TMCnet News
Cognision Launches Cognision360™: A Uni?ed Platform Transforming Neurobiomarker Acquisition, Processing, and Analysis in CNS Clinical TrialsLOUISVILLE, Ky., Feb. 3, 2026 /PRNewswire/ -- Cognision today unveiled Cognision360™, a groundbreaking web-based platform that consolidates multiple neurobiomarker data streams into a single, standardized system—addressing one of the pharmaceutical industry's most persistent challenges in central nervous system (CNS) drug development. The Challenge: Fragmented Data, Complex Trials Cognision360™ changes this paradigm. One Platform, Multiple Data Streams, Zero Compromise What makes this signi?cant? Every data point captured through Cognision360™ is automatically tagged with comprehensive study metadata—subject ID, site location, treatment arm, visit timepoint—from the moment of collection. This eliminates the manual data transcription and ?le transfers that plague traditional approaches, dramatically reducing errors and accelerating the path to database lock. "We're seeing sponsors invest millions in sophisticated biomarker strategies, only to lose weeks or months wrestling with data integration issues," said Dr. Igor Korolev, Vice President of Neuroscience and Digital Health at Cognision."Cognision360™ provides an end-to-end framework that ensures multi-modal neurobiomarker data meets regulatory expectations for consistency and integrity from day one." Built for Real-World Clinical Operations
Protocol-de?ned work?ows embedded in the software ensure consistency across sites, users, and timepoints—addressing a critical FDA and EMA concern in digital health technology deployment. Transparency Over Black Boxes "The platform employs deterministic, rules-based analytical methods with expert-de?ned data relationships rather than non-transparent arti?cial intelligence models," explained K.C. Fadem, Chief Technology Officer. "For regulatory submissions, transparency, reproducibility, and traceability aren't nice-to-haves—they're requirements. Our approach is designed with that reality in mind." Enables FDA's New Bayesian Trial Guidelines Enterprise-Grade Infrastructure, Research-Grade Flexibility Study data remains continuously accessible through secure web interfaces for remote monitoring and analysis by authorized users—critical for decentralized trial models and real-time decision-making. At any stage of a study, data can be exported in formats ready for regulatory submissions, streamlining the transition from data collection to ?ling. About Cognision FOR MEDIA INQUIRIES:
SOURCE Cognision
|
